DOCSLIB.ORG

Neuronal Signaling Pathways: Genetic Insights Into the Pathophysiology Of

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

............................................................................................................................................................... HOT TOPICS 350 DISCLOSURE carry a (1;11)(q42.1; q14.3) translo- neuronal migration, axon guidance, In addition to income received from his primary cation; the chromosome 1 transloca- synapse formation, myelination, employer, Dr David Steffens has received honoraria for speaking at educational activities sponsored by tion break point falls between exon and oligodendrocyte development. Forest Pharmaceuticals and Wyeth Pharmaceuticals. 8 and 9 of DISC1, presumably result- NRG-1 activated Akt inhibits GSK3b, This work was partially supported by National Institute ing in loss of DISC1 expression. tying NRG1 signaling to Wnt and of Mental Health Grants P50 MH60451, R01 MH54846, and K24 MH70027. This finding has launched an entire DISC1 activity. The related effects ..................................................................... subfield of schizophrenia genetics and of DISC1 and NRG1 have been high- Alexopoulos GS, Meyers BS, Young RC, Campbell S, neurobiology, with an emphasis on lighted in a zebrafish model, in Silbersweig D, Charlson M (1997). ‘Vascular the role of the DISC1 gene product and which DISC1 loss produced develop- depression’ hypothesis. Arch Gen Psychiatry 54: 915–922. its protein interaction partners in mental deficits very similar to loss Pan CC, McQuoid DR, Taylor WD, Payne ME, Ashley- neurodevelopment and synaptic func- of NRG1 signaling, including failure of Koch A, Steffens DC (2009). Association analysis tion (Chubb et al, 2008). normal oligodendrocyte development of the COMT/MTHFR genes and geriatric depres- sion: An MRI study of the putamen. Int J Geriatr In the past year, DISC1 has been put and near total failure of olig2-positive Psychiatry 24: 847–855. into the context of key signal trans- cerebellar neuron development Qiu A, Taylor WD, Zhao Z, MacFall JR, Miller MI, Key duction pathways and other genetic (Wood et al, 2009). The effect of CR et al (2009). APOE related hippocampal shape alteration in geriatric depression. Neuroimage 44: findings. In one critical study psychotropic agents on these path- 620–626. (Mao et al, 2009), DISC1 was shown ways provides an additional link to Steffens DC, Taylor WD, McQuoid DR, Krishnan KR to modulate the ‘canonical’ Wnt- major mental illness. For instance, (2008). Short/long heterozygotes at 5HTTLPR and white matter lesions in geriatric depression. Int signaling pathway. This pathway lithium activates Akt and inhibits J Geriatr Psychiatry 23: 244–248. (Komiya and Habas, 2008) is activated GSK3b, whereas antipsychotic agents, Taylor WD, Zu¨ chner S, McQuoid DR, Payne ME, when a member of the Wnt family by antagonism of D2 receptors, MacFall JR, Steffens DC et al (2008). The brain- derived neurotrophic factor VAL66MET poly- of secreted glycoproteins binds a block the stimulatory effect of dopa- morphism and cerebral white matter hyperinten- member of the Frizzled receptor mine on Akt. sities in late-life depression. Am J Geriatr family along with coreceptors. Path- Overall, the convergence of genetic, Psychiatry 16: 263–271. Taylor WD, Steffens DC, Ashley-Koch A, Payne ME, way activation reduces GSK3b kinase pharmacological, and neurobiologi- MacFall JR, Potocky C et al (2009). Angiotensin activity, resulting in diminished phos- cal data have opened the door to receptor gene polymorphisms and 2-year phorylation of b-catenin. Unpho- multiple novel potential therapeutic change in cerebral hyperintense lesion volume in men. Mol Psychiatry, March 10 (E-pub ahead sphorylated b-catenin accumulates in targets in the DISC1–Wnt–NRG1 sys- of print). the cytoplasm and is translocated into tems, and this neurogenetic approach the nucleus, where it functions as a holds considerable promise for Neuropsychopharmacology Reviews (2010) 35, 349–350; doi:10.1038/npp.2009.135 transcriptional coactivator. Among future research. For instance, the other effects, this transcriptional recent association of the MHC locus activity can drive neuronal neurogen- on chromosome 6p with schizophre- esis. DISC1 directly interacts with nia (e.g., Stefansson et al, 2009) GSK3b, inhibiting GSK3b phosphor- supports the long standing concept ylation of b-catenin and thus increas- that environmental factors such as Neuronal signaling ing b-catenin-induced transcriptional infection may have a role in schizo- pathways: genetic activity. The effect is to mimic Wnt phrenia, and provides a rationale for insights into the pathway activation. Loss of DISC1 models of disease that encompass inhibits b-catenin-induced transcrip- both genetic and environmental fac- pathophysiology of tion, providing a potential mechanism tors. Associations of neurogranin on major mental illness by which DISC1 loss of function 11q24.2 and transcription factor 4 mutations might exert their effect. (TCF4) on 18q21.2 with schizophrenia Psychiatric genetics has turned a DISC1 has also been linked to (Stefansson et al, 2009) may lead to cornerFincreasingly robust findings pathways involving Neuregulin-1 new pathways with additional thera- can be placed in a neurobiological (NRG1), one of the most robust peutic targets. Psychiatric research has context, with practical implications candidate genes for schizophrenia entered an era in which genetic for understanding disease pathogen- (Mei and Xiong 2008). Extracellular findings implicate specific signaling esis and developing of therapeutics. NRG1, cleaved from Pro-NRG1, inter- pathways, leading to new insights into A milestone in this effort was the acts with and activates the ErbB family disease pathogenesis and the develop- discovery of the DISC1 (disrupted in of receptor protein kinases (ErbB2, 3, ment of new approaches to therapeutics. Schizophrenia 1) gene, found via 4, and EGFR), starting a cascade that 1,2,3 analysis of a large Scottish family Russell L Margolis and activates a number of partially over- 1,2,3,4 with a high rate of schizophrenia lapping pathways, including RafF Christopher A Ross 1Division of Neurobiology, Department of Psychiatry, and psychotic affective disorder. MEK–ERK and PI3K–Akt. NRG1 Johns Hopkins University School of Medicine, All affected members of the family signaling has been implicated in Baltimore, MD, USA; .............................................................................................................................................. Neuropsychopharmacology HOT TOPICS ............................................................................................................................................................... 351 2 Department of Neurology, Johns Hopkins University We reported (Boldrini et al, 2009) gration into brain circuits that regulate School of Medicine, Baltimore, MD, USA; 3Program in Cellular and Molecular Medicine, Johns that selective serotonin reuptake in- emotional responses to the environ- Hopkins University School of Medicine, Baltimore, hibitors and tricyclic antidepressants ment. MD, USA and increase dividing and neural progeni- In our study, the antidepressant- 4Departments of Pharmacology and Neuroscience, Johns Hopkins University School of Medicine, tor cells (NPCs) in the DG of depre- induced increase in NPCs and Baltimore, MD, USA ssed subjects (MDD), compared with dividing cells was associated with a E-mail: [email protected] untreated MDD patients or controls. larger volume of DG. Antidepressant In humans, antidepressants increase treatment is known to increase DISCLOSURE Potential conflicts of interest for RLM: Consultant the number of mitotic cells of all hippocampal volume in posttraumatic for AstraZeneca, grant support from Medivation, phenotypes in the DG, regardless of stress disorder (Bossini et al, 2007), Amarin, Pfizer, and Forest Pharmaceuticals. age. On the other hand, replication of but no similar data are available in No conflicts of interest for CAR. NPCs, as in lower mammals, decreases depression, although patients with ..................................................................... with age (Couillard-Despres et al, MDD have a smaller hippocampus. Chubb JE, Bradshaw NJ, Soares DC, Porteous DJ, Millar JK (2008). The DISC locus 2009). This might explain why there The volume increase could be related in psychiatric illness. Mol Psychiatry 13: is a poor antidepressant response in to a restoration of cell number or 36–64. the elderly. neuropil, as antidepressants reverse Komiya Y, Habas R (2008). Wnt signal transduction pathways. Organogen 4: 68–75. The functional relevance of the dendritic shrinkage and improve cell Mao Y, Ge X, Frank CL, Madison JM, enhancement of neurogenesis by anti- survival, activating the antiapoptotic Koehler AN, Doud MK et al. (2009). Disrupted in depressants needs to be ascertained by protein Bcl-2 and brain-derived schizophrenia 1 regulates neuronal progenitor proliferation via modulation of GSK3beta/beta- determining whether increased cell neurotrophic factor expression in catenin signaling. Cell 136: 1017–1031. proliferation is associated with im- mammals. Mei L, Xiong WC (2008). Neuregulin 1 in neural provement of symptoms in MDD. In Future studies must determine development, synaptic plasticity and schizophre- nia. Nat Rev Neurosci 9: 437–452. our study (Boldrini et al, 2009), a whether antidepressant response is Stefansson H, Ophoff RA, Steinberg S, Andreassen significant proportion of subjects died linked to increased neurogenesis, but OA, Cichon S, Rujescu D et al. (2009). Common by
Recommended publications
  • Antidepressants Increase Human Hippocampal Neurogenesis By

    Antidepressants Increase Human Hippocampal Neurogenesis By

    Molecular Psychiatry (2011) 16, 738–750 & 2011 Macmillan Publishers Limited All rights reserved 1359-4184/11 www.nature.com/mp ORIGINAL ARTICLE Antidepressants increase human hippocampal neurogenesis by activating the glucocorticoid receptor C Anacker1,2,3, PA Zunszain1, A Cattaneo1,4, LA Carvalho1, MJ Garabedian5, S Thuret3, J Price3 and CM Pariante1,2 1King’s College London, Institute of Psychiatry, Section of Perinatal Psychiatry and Stress, Psychiatry and Immunology (SPI-lab), Department of Psychological Medicine, London, UK; 2National Institute for Health Research ‘Biomedical Research Centre for Mental Health’, Institute of Psychiatry and South London and Maudsley NHS Foundation Trust, London, UK; 3King’s College London, Institute of Psychiatry, Centre for the Cellular Basis of Behaviour (CCBB), London, UK; 4Genetics Unit, IRCCS San Giovanni di Dio, Brescia, Italy and 5Department of Microbiology, NYU School of Medicine, New York, NY, USA Antidepressants increase adult hippocampal neurogenesis in animal models, but the underlying molecular mechanisms are unknown. In this study, we used human hippocampal progenitor cells to investigate the molecular pathways involved in the antidepressant-induced modulation of neurogenesis. Because our previous studies have shown that antidepressants regulate glucocorticoid receptor (GR) function, we specifically tested whether the GR may be involved in the effects of these drugs on neurogenesis. We found that treatment (for 3–10 days) with the antidepressant, sertraline, increased neuronal differentiation via a GR-dependent mechanism. Specifically, sertraline increased both immature, double- cortin (Dcx)-positive neuroblasts ( þ 16%) and mature, microtubulin-associated protein-2 (MAP2)-positive neurons ( þ 26%). This effect was abolished by the GR-antagonist, RU486. Interestingly, progenitor cell proliferation, as investigated by 50-bromodeoxyuridine (BrdU) incorporation, was only increased when cells were co-treated with sertraline and the GR-agonist, dexamethasone, ( þ 14%) an effect which was also abolished by RU486.
  • The Antidepressant Effect of Testosterone an Effect Of

    The Antidepressant Effect of Testosterone an Effect Of

    Neurology, Psychiatry and Brain Research 32 (2019) 104–110 Contents lists available at ScienceDirect Neurology, Psychiatry and Brain Research journal homepage: www.elsevier.com/locate/npbr The antidepressant effect of testosterone: An effect of neuroplasticity? T ⁎ Andreas Walthera,b,c, , Joanna Marta Wasielewskad, Odette Leitere a Biological Psychology, Technische Universität Dresden, Dresden, Germany b Clinical Psychology and Psychotherapy, University of Zurich, Zurich, Switzerland c Task Force on Men’s Mental Health of the World Federation of the Societies of Biological Psychiatry (WFSBP), Germany d Center for Regenerative Therapies (CRTD), Technische Universität Dresden, Germany e Queensland Brain Institute (QBI), University of Queensland, St Lucia, QLD, 4072, Australia ARTICLE INFO ABSTRACT Keywords: Background: Rodent and human studies indicate that testosterone has an antidepressant effect. The mechanisms Testosterone via which testosterone exerts its antidepressant effect, however, remain to be elucidated. Some studies assume Depression downstream effects of testosterone on sexual function and vitality followed by improvement of mood. Emerging Men evidence suggests that testosterone may be acting in the brain within depression-relevant areas, whereby eli- Neurogenesis citing direct antidepressant effects, potentially via neuroplasticity. Neuroplasticity Methods: Literature was searched focusing on testosterone treatment and depression and depression-like be- Antidepressant havior. Due to the unilateral clinical use of testosterone in men and the different modes of action of sex hor- mones in the central nervous system in men and women, predominantly studies on male populations were identified. Results: The two proposed mechanisms via which testosterone might act as antidepressant in the central nervous system are the support of neuroplasticity as well as the activation of the serotonin system.
  • Stress Hormones Trk Neurons Into Survival

    Stress Hormones Trk Neurons Into Survival

    RESEA r CH HIGHLIGHTS M olec U lar ne U roscience Similar to the in vivo experi- ments, Dex treatment of cultured neurons did not increase levels of Stress hormones Trk BDNF, NGF or NT3, suggesting that the neuroprotective effect of Dex is independent of neurotrophin release. neurons into survival Administration of an inhibitor of the PI3K–AKT pathway abolished Dex- which adult neurogenesis occurs. mediated neuroprotection, whereas Surprisingly, Dex administration did adding a Trk inhibitor only reduced not alter levels of the neurotrophins it; thus, glucocorticoids might also nerve growth factor (NGF), brain- stimulate the PI3K–AKT pathway derived neurotrophic factor (BDNF) through a route that does not involve and neurotrophin 3 (NT3) in the hip- TrkB phosphorylation. pocampus or in the parietal cortex, The mechanism by which gluco- indicating that the phosphorylation corticoids activate Trks is unknown of TrkB by glucocorticoids did not but probably involves the gluco- require increased neurotrophin corticoid receptor, as addition of a production. glucocorticoid receptor antagonist Phosphorylated Trks are activated abolished Dex-mediated neuropro- tyrosine kinases, which can phospho- tection. The glucocorticoid effects rylate other proteins. Thus, adding were slow and lasted for several Glucocorticoids have a bad reputa- Dex or BDNF (the main ligand for hours, which is suggestive of genomic tion. However, although these stress the TrkB receptor) to cortical slices actions. Indeed, Trk activation by hormones can be neurotoxic in activated TrkB and phosphorylated Dex could be abolished by actinomy- high levels, they are also required the intracellular signalling molecules cin D and cycloheximine, inhibitors for neuronal survival, and they AKT, phospholipase Cγ (PLCγ) and of transcription and translation, promote neuronal growth and dif- extracellular signal-regulated kinase respectively.
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
  • DISC1 a Key Molecular Lead in Psychiatry and Neurodevelopment: No-More Disrupted-In-Schizophrenia 1

    DISC1 a Key Molecular Lead in Psychiatry and Neurodevelopment: No-More Disrupted-In-Schizophrenia 1

    Molecular Psychiatry (2016) 21, 1488–1489 © 2016 Macmillan Publishers Limited, part of Springer Nature. All rights reserved 1359-4184/16 www.nature.com/mp NEWS AND COMMENTARY DISC1 a key molecular lead in psychiatry and neurodevelopment: No-More Disrupted-in-Schizophrenia 1 M Niwa1, T Cash-Padgett1,4, K-I Kubo2,4, A Saito1,4, K Ishii1,4, A Sumitomo3, Y Taniguchi1, K Ishizuka1, H Jaaro-Peled1, T Tomoda3, K Nakajima2, A Sawa1 and A Kamiya1 Molecular Psychiatry (2016) 21, 1488–1489; doi:10.1038/ second, although DISC1 is a multifunctional intracellular hub mp.2016.154; published online 6 September 2016 protein, we still do not know which specific function of DISC1 underlies each endophenotype or phenotype in mental conditions. Since the middle of the past century, we have serendipitously To address the first question on genetic validity, Sullivan7 come across treatment regimens that can partially ameliorate pointed out that DISC1 is unlikely to be an important ‘genetic’ psychosis and depression. Nonetheless, the mechanisms under- factor for schizophrenia defined by the Diagnostic and Statistical lying such severe mental conditions still remain elusive. Such lack Manual of Mental Disorders (DSM). This discussion is fairly valid, of mechanistic insight into major mental illnesses has hampered and we agree with this statement and conclude as ‘No-More the establishment of precise diagnostic framework, precluding Disrupted-in-Schizophrenia 1.’ Regarding the second question, Tsuboi further discovery of fundamental treatments for these disorders. et al.8 have recently encouraged the field to reinforce the evidence Meanwhile, understanding of the brain at the molecular level that supports the role for DISC1 in early development.
  • Trkb Receptor Controls Striatal Formation by Regulating the Number of Newborn Striatal Neurons

    Trkb Receptor Controls Striatal Formation by Regulating the Number of Newborn Striatal Neurons

    TrkB receptor controls striatal formation by regulating the number of newborn striatal neurons Maryna Baydyuka, Theron Russella, Guey-Ying Liaoa, Keling Zangb, Juan Ji Ana, Louis French Reichardtb, and Baoji Xua,1 aDepartment of Pharmacology, Georgetown University Medical Center, Washington, DC 20057; and bDepartment of Physiology, University of California, San Francisco, CA 94158 Edited* by Michael P. Stryker, University of California, San Francisco, CA, and approved November 19, 2010 (received for review April 8, 2010) In the peripheral nervous system, target tissues control the final son disease (6, 7). Approximately 95% of striatal neurons are size of innervating neuronal populations by producing limited medium-sized spiny neurons (MSNs) with the rest being inter- amounts of survival-promoting neurotrophic factors during de- neurons (8). MSNs, which use γ-aminobutyric acid (GABA) as velopment. However, it remains largely unknown if the same a transmitter, are born in the lateral ganglionic eminence (LGE) principle works to regulate the size of neuronal populations in the and migrate to the striatum during embryogenesis (9). They are developing brain. Here we show that neurotrophin signaling divided into two populations based on their projection sites. mediated by the TrkB receptor controls striatal size by promoting MSNs at the origin of the direct pathway directly project to the the survival of developing medium-sized spiny neurons (MSNs). output nuclei of the basal ganglia, such as the internal segment of Selective deletion of the gene for the TrkB receptor in striatal the globus pallidus, the substantia nigra pars reticulata, and the progenitors, using the Dlx5/6-Cre transgene, led to a hindpaw- ventral pallidum.
  • Regulation of Adult Neurogenesis in Mammalian Brain

    Regulation of Adult Neurogenesis in Mammalian Brain

    International Journal of Molecular Sciences Review Regulation of Adult Neurogenesis in Mammalian Brain 1,2, 3, 3,4 Maria Victoria Niklison-Chirou y, Massimiliano Agostini y, Ivano Amelio and Gerry Melino 3,* 1 Centre for Therapeutic Innovation (CTI-Bath), Department of Pharmacy & Pharmacology, University of Bath, Bath BA2 7AY, UK; [email protected] 2 Blizard Institute of Cell and Molecular Science, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, UK 3 Department of Experimental Medicine, TOR, University of Rome “Tor Vergata”, 00133 Rome, Italy; [email protected] (M.A.); [email protected] (I.A.) 4 School of Life Sciences, University of Nottingham, Nottingham NG7 2HU, UK * Correspondence: [email protected] These authors contributed equally to this work. y Received: 18 May 2020; Accepted: 7 July 2020; Published: 9 July 2020 Abstract: Adult neurogenesis is a multistage process by which neurons are generated and integrated into existing neuronal circuits. In the adult brain, neurogenesis is mainly localized in two specialized niches, the subgranular zone (SGZ) of the dentate gyrus and the subventricular zone (SVZ) adjacent to the lateral ventricles. Neurogenesis plays a fundamental role in postnatal brain, where it is required for neuronal plasticity. Moreover, perturbation of adult neurogenesis contributes to several human diseases, including cognitive impairment and neurodegenerative diseases. The interplay between extrinsic and intrinsic factors is fundamental in regulating neurogenesis. Over the past decades, several studies on intrinsic pathways, including transcription factors, have highlighted their fundamental role in regulating every stage of neurogenesis. However, it is likely that transcriptional regulation is part of a more sophisticated regulatory network, which includes epigenetic modifications, non-coding RNAs and metabolic pathways.
  • Amitriptyline-Mediated Cognitive Enhancement in Aged 36Tg Alzheimer’S Disease Mice Is Associated with Neurogenesis and Neurotrophic Activity

    Amitriptyline-Mediated Cognitive Enhancement in Aged 36Tg Alzheimer’S Disease Mice Is Associated with Neurogenesis and Neurotrophic Activity

    Amitriptyline-Mediated Cognitive Enhancement in Aged 36Tg Alzheimer’s Disease Mice Is Associated with Neurogenesis and Neurotrophic Activity Wayne Chadwick1, Nick Mitchell2, Jenna Caroll3, Yu Zhou1, Sung-Soo Park1, Liyun Wang1, Kevin G. Becker4, Yongqing Zhang4, Elin Lehrmann4, William H. Wood III4, Bronwen Martin5, Stuart Maudsley1* 1 Receptor Pharmacology Unit, National Institute on Aging, National Institutes of Health, Baltimore, Maryland, United States of America, 2 Laboratory of Neurosciences, National Institute on Aging, National Institutes of Health, Baltimore, Maryland, United States of America, 3 Center for Neurodegenerative Disease Research, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America, 4 Genomics Unit, Research Resources Branch, National Institute on Aging, National Institutes of Health, Baltimore, Maryland, United States of America, 5 Metabolism Unit, National Institute on Aging, National Institutes of Health, Baltimore, Maryland, United States of America Abstract Approximately 35 million people worldwide suffer from Alzheimer’s disease (AD). Existing therapeutics, while moderately effective, are currently unable to stem the widespread rise in AD prevalence. AD is associated with an increase in amyloid beta (Ab) oligomers and hyperphosphorylated tau, along with cognitive impairment and neurodegeneration. Several antidepressants have shown promise in improving cognition and alleviating oxidative stress in AD but have failed as long- term therapeutics. In this study, amitriptyline, an FDA-approved tricyclic antidepressant, was administered orally to aged and cognitively impaired transgenic AD mice (36TgAD). After amitriptyline treatment, cognitive behavior testing demonstrated that there was a significant improvement in both long- and short-term memory retention. Amitriptyline treatment also caused a significant potentiation of non-toxic Ab monomer with a concomitant decrease in cytotoxic dimer Ab load, compared to vehicle-treated 36TgAD controls.
  • The TRAX, DISC1, and GSK3 Complex in Mental Disorders and Therapeutic Interventions Yu-Ting Weng1,2, Ting Chien1, I-I Kuan1 and Yijuang Chern1,2*

    The TRAX, DISC1, and GSK3 Complex in Mental Disorders and Therapeutic Interventions Yu-Ting Weng1,2, Ting Chien1, I-I Kuan1 and Yijuang Chern1,2*

    Weng et al. Journal of Biomedical Science (2018) 25:71 https://doi.org/10.1186/s12929-018-0473-x REVIEW Open Access The TRAX, DISC1, and GSK3 complex in mental disorders and therapeutic interventions Yu-Ting Weng1,2, Ting Chien1, I-I Kuan1 and Yijuang Chern1,2* Abstract Psychiatric disorders (such as bipolar disorder, depression, and schizophrenia) affect the lives of millions of individuals worldwide. Despite the tremendous efforts devoted to various types of psychiatric studies and rapidly accumulating genetic information, the molecular mechanisms underlying psychiatric disorder development remain elusive. Among the genes that have been implicated in schizophrenia and other mental disorders, disrupted in schizophrenia 1 (DISC1) and glycogen synthase kinase 3 (GSK3) have been intensively investigated. DISC1 binds directly to GSK3 and modulates many cellular functions by negatively inhibiting GSK3 activity. The human DISC1 gene is located on chromosome 1 and is highly associated with schizophrenia and other mental disorders. A recent study demonstrated that a neighboring gene of DISC1, translin-associated factor X (TRAX), binds to the DISC1/GSK3β complex and at least partly mediates the actions of the DISC1/GSK3β complex. Previous studies also demonstrate that TRAX and most of its interacting proteins that have been identified so far are risk genes and/or markers of mental disorders. In the present review, we will focus on the emerging roles of TRAX and its interacting proteins (including DISC1 and GSK3β) in psychiatric disorders and the potential implications for developing therapeutic interventions. Keywords: TRAX, DISC1, GSK3β, Mental disorders, DNA damage, DNA repair, Oxidative stress, A2AR, PKA Background DNA repair) by interacting with various proteins [4–12].
  • Effects of Neuregulin-1 Administration on Neurogenesis in the Adult Mouse

    Effects of Neuregulin-1 Administration on Neurogenesis in the Adult Mouse

    www.nature.com/scientificreports OPEN Effects of neuregulin-1 administration on neurogenesis in the adult mouse hippocampus, Received: 30 January 2016 Accepted: 04 July 2016 and characterization of immature Published: 29 July 2016 neurons along the septotemporal axis Ian Mahar1,2, Angus MacIsaac1, John Junghan Kim1, Calvin Qiang1, Maria Antonietta Davoli1, Gustavo Turecki1,2,3 & Naguib Mechawar1,2,3 Adult hippocampal neurogenesis is associated with learning and affective behavioural regulation. Its diverse functionality is segregated along the septotemporal axis from the dorsal to ventral hippocampus. However, features distinguishing immature neurons in these regions have yet to be characterized. Additionally, although we have shown that administration of the neurotrophic factor neuregulin-1 (NRG1) selectively increases proliferation and overall neurogenesis in the mouse ventral dentate gyrus (DG), likely through ErbB3, NRG1’s effects on intermediate neurogenic stages in immature neurons are unknown. We examined whether NRG1 administration increases DG ErbB3 phosphorylation. We labeled adultborn cells using BrdU, then administered NRG1 to examine in vivo neurogenic effects on immature neurons with respect to cell survival, morphology, and synaptogenesis. We also characterized features of immature neurons along the septotemporal axis. We found that neurogenic effects of NRG1 are temporally and subregionally specific to proliferation in the ventral DG. Particular morphological features differentiate immature neurons in the dorsal and ventral DG, and cytogenesis differed between these regions. Finally, we identified synaptic heterogeneity surrounding the granule cell layer. These results indicate neurogenic involvement of NRG1-induced antidepressant- like behaviour is particularly associated with increased ventral DG cell proliferation, and identify novel distinctions between dorsal and ventral hippocampal neurogenic development.
  • DISC1-Binding Proteins in Neural Development, Signalling and Schizophrenia

    DISC1-Binding Proteins in Neural Development, Signalling and Schizophrenia

    Edinburgh Research Explorer DISC1-binding proteins in neural development, signalling and schizophrenia Citation for published version: Bradshaw, NJ & Porteous, DJ 2012, 'DISC1-binding proteins in neural development, signalling and schizophrenia', Neuropharmacology, vol. 62, no. 3, pp. 1230-41. https://doi.org/10.1016/j.neuropharm.2010.12.027 Digital Object Identifier (DOI): 10.1016/j.neuropharm.2010.12.027 Link: Link to publication record in Edinburgh Research Explorer Document Version: Publisher's PDF, also known as Version of record Published In: Neuropharmacology Publisher Rights Statement: Available under Open Access General rights Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 25. Sep. 2021 Neuropharmacology 62 (2012) 1230e1241 Contents lists available at ScienceDirect Neuropharmacology journal homepage: www.elsevier.com/locate/neuropharm DISC1-binding proteins in neural development, signalling and schizophrenia Nicholas J. Bradshaw*, David J. Porteous Medical Genetics Section, Molecular Medicine Centre, Institute of Genetics & Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road South, Edinburgh, Midlothian EH4 2XU, UK article info abstract Article history: In the decade since Disrupted in Schizophrenia 1 (DISC1)wasfirst identified it has become one of the most Received 29 October 2010 convincing risk genes for major mental illness.
  • Androgens Enhance Adult Hippocampal Neurogenesis in Males but Not Females in an Age

    Androgens Enhance Adult Hippocampal Neurogenesis in Males but Not Females in an Age

    bioRxiv preprint doi: https://doi.org/10.1101/539296; this version posted February 3, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 Androgens enhance adult hippocampal neurogenesis in males but not females in an age- 2 dependent manner 3 4 Paula Duarte-Guterman1, Dwayne K. Hamson1, Steven R. Wainwright1, Carmen Chow1, Jessica 5 Chaiton1, Stephanie Lieblich1, Neil V. Watson2, Liisa A.M. Galea1 6 7 1. Djavad Mowafaghian Centre for Brain Health and Department of Psychology, University of 8 British Columbia, Vancouver, BC, Canada 9 2. Department of Psychology, Simon Fraser University, Burnaby, BC, Canada 10 11 12 Address all correspondence and requests for reprints to: 13 L. A. M. Galea, PhD, 14 Djavad Mowafaghian Centre for Brain Health 15 2215 Wesbrook Mall 16 Vancouver, British Columbia 17 V6T 1Z3, Canada 18 2136 West Mall, Vancouver, 19 British Columbia, V6T 1Z4, Canada. 20 E-mail: [email protected]. 1 bioRxiv preprint doi: https://doi.org/10.1101/539296; this version posted February 3, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 21 Abstract 22 Androgens (testosterone and dihydrotestosterone) increase adult hippocampal 23 neurogenesis by increasing new neuron survival in male rats and mice via an androgen receptor 24 pathway, but it is not known whether androgens regulate neurogenesis in females and whether 25 the effect is age-dependent.